Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors
NL79259.078.21
Phase 1 other active
Quick answer
Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors for locally advanced or metastatic, well-differentiated gastro-enteropancreatic neuroendocrine tumors. is a Phase 1 program (other) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- locally advanced or metastatic, well-differentiated gastro-enteropancreatic neuroendocrine tumors.
- Phase
- Phase 1
- Modality
- other
- Status
- active